Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 Jun 15;21(2):168. doi: 10.1016/S1473-3099(20)30466-7

Seroconversion in household members of COVID-19 outpatients

Rebecca J Cox a,d, Karl A Brokstad b, Florian Krammer f, Nina Langeland c,e; Bergen COVID-19 Research Group, for the
PMCID: PMC7295487  PMID: 32553187

We read with interest the Article by Qifang Bi and colleagues,1 in which they reported a household secondary attack rate, as detected by repeated RT-PCR tests, of approximately 11%. We have found substantially higher attacks rates in western Norway through detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The first case of COVID-19 in Norway was identified in Bergen on Feb 28, 2020, before the outbreak was declared a pandemic, allowing rigorous testing of suspected cases before and during the rise in confirmed cases. All suspected COVID-19 cases in the peak period between Feb 28 and April 4 were referred to the Bergen municipality emergency room for centralised evaluation and testing according to a strict exposure likelihood algorithm, allowing an overview of the early virus spread in the population. If a family was exposed, only the index case was tested for SARS-CoV-2 infection. Both cases and household members were tested for specific antibodies to the receptor binding domain of SARS-CoV-2, as described by Stadlbauer and colleagues,2 at 6 weeks after the index patient tested positive by RT-PCR.

Of 158 cases, 125 (79%) tested positive for antibodies and 12 (8%) were defined as borderline. In 77 household members, 24 (31%) tested positive and two (3%) were borderline. Our results show that detection of seroconversion might provide a more accurate picture of attack rates in households than intermittent RT-PCR testing.

Acknowledgments

FK reports that an assay used to screen for seroconversion was developed in his laboratory and that Mount Sinai has filed patent applications to protect that assay, has licensed its use for several companies, and is commercialising the assay. All other authors declare no competing interests.

Contributor Information

Bergen COVID-19 Research Group:

Bjørn Blomberg, Kanika Kuwelker, Sarah Lartey, Dagrun Waag Linchausen, Kristin GI Mohn, Francisco Gomez Real, Amit Bansal, Geir Bredholt, Anders Madsen, Therese Bredholt Onanygo, Mai Chi Trieu, Juha Vahokoski, and Fan Zhou

Supplementary Material

Supplementary appendix
mmc1.pdf (127.2KB, pdf)

References

  • 1.Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30287-5. published online April 27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 doi: 10.1038/s41591-020-0913-5. published online May 12. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary appendix
mmc1.pdf (127.2KB, pdf)

Articles from The Lancet. Infectious Diseases are provided here courtesy of Elsevier

RESOURCES